QUICKLINKS AND VIEW OPITONS
Contrave (400 mg Wellbutrin + 32 mg naltrexone): 7.9% dropouts; with 48 mg naltrexone, 18% dropouts
Monday, October 22, 2007 6:18 am Email this article
Drop out rates for the first six months for those given Contrave, with various doses of Wellbutrin (bupropion) and naltrexone, were 7.9 percent for those given 32 mg of naltrexone plus 400 mg of Wellbutrin (bupropion) compared to 18 percent for those given 48 mg of naltrexone plus 400 mg of Wellbutrin (bupropion) according to a press release from Orexigen Therapeutics, the company developing this drug combination. REFERENCE
Greenway F, Fujioka K, Anderson J, Raj YP, Gupta A, O’neil P, Smith D, Schumacher D, Guttadauria M, Dunayevich E, Cruickshank S, Cowley M, Tollefson G. Orexigen therapeutics reports a summary of results from the phase iib trial of contrave to treat obesity. Press Release from Orexigen Therapeutics, Data presented at The Obesity Society’s Annual Scientific Meeting in New Orleans, October 20-24, 2007. Press Release dated 2007 Oct 21.
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.